Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
0
Like
Facebook
Tweet
Print
Session IV: BTKi in the Treatment of CLL
Comparing BTK Inhibitors In CLL Therapy – What’s Old, What’s New, What’s Tried, What’s True?
Wednesday, May 11, 2022
3:10 PM – 3:30 PM
Speaker(s)
Susan O’Brien, MD
Professor of Medicine
University of California Irvine
Laguna, California
Learning Objectives:
Compare the efficacy and safety data for current and emerging BTK inhibitors for the treatment of CLL/SLL
Evaluate long-term patient outcomes data for BTK inhibitors in the treatment of CLL/SLL
Anticipate and manage adverse events when treating patients with CLL/SLL with BTK inhibitors and with combined targeted therapy